Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel injection for previously treated advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
CTR20181676Phase 2Active
- Sponsor
- Kelun-Biotech
- Start
- Oct 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Kelun-Biotech. Started Oct 2018; status: active.
02
Drugs
cabazitaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20181676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181676.